OVARIAN CANCER

Ovarian cancer is the worst prognosis of gynecologic tumors. Patients with advanced epithelial ovarian cancer five-year survival rates generally below 30%, mainly in patients with relapsing most (about 75%), relapse after chemotherapy to poor results.

For the treatment of recurrent ovarian cancer chemotherapy drugs many, no less than 10 species, but only clinical remission rate of 20% to 30%, no progress median survival time (PFS) for 2 to 6 months, the median overall survival (OS) for six to 12 months. Therefore, to improve the efficacy of chemotherapy drugs delay, but the development of new drugs is very difficult, efficient use of existing drugs is an effective way to <BR>.

Tags: cancer, cases, chemotherapy, cisplatin, clinical, drug, drugs, early, eat, exploration, gene, group, method, ovarian, p53, paclitaxel, patients, pmtc, poor, positive, prognosis, rate, second, study, survival, taxol, therapy, time, treatment, tumor, tumors

A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understanding, abdominal local cytotoxic drug treatment for ovarian cancer is very reasonable. Intraperitoneal chemotherapy Phase I clinical trial confirmed the chemotherapy drugs and intraperitoneal chemotherapy safety of the technology itself, confirmed the intraperitoneal chemotherapy in the pharmacokinetic advantages.

In some multi-center Phase II clinical trials, surgical results confirmed that about 20% to 40% of second-tier category to cisplatin-based chemotherapy in patients with celiac complete remission, the part of the residual cancer patients <0.5 cm before  acceptable to platinum-based chemotherapy effective systemic System .

Tags: abdominal, administration, age, cancer, carboplatin, cause, chemotherapy, cisplatin, clinical, days, drug, drugs, eat, group, incidence, infusion, injection, intraperitoneal, intravenous, ovarian, paclitaxel, pain, patients, rate, reduce, residual, second, study, surgical, survival, taxol, therapy, time, toxicity, treatment, tumor

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women

Abstract: a group P53 mutations in the genes in patients with advanced ovarian cancer by more cycles of P53 gene therapy and chemotherapy, reducing disease, the survival rate has improved. (The Fourth Annual Gene Therapy & Molecular Biology Conference, Rhodes, Greece)

American University of Iowa Dr. Richard Buller reported they received early treatment to strengthen the 36 patients with advanced ovarian cancer to the adenovirus vector into the peritoneal tumor suppressor gene p53 function of the combination of chemotherapy I / II clinical trials of the preliminary results. The results show that several gene therapy / chemotherapy combination therapy in patients with an average survival of 14.8. Nine people have survived 19.5 months, are still alive. The survival rate is higher than five separate gene therapy on the survival rate is also higher than the average with paclitaxel (Taxol) in the treatment of recurrent ovarian cancer new 15-month survival rate.

Tags: age, cancer, carboplatin, cause, chemotherapy, clinical, early, eat, gene, group, intraperitoneal, mutation, ovarian, p53, paclitaxel, patients, rate, reduce, survival, taxol, therapy, treatment, tumor

Kikuchi, the Japanese report, have received platinum multidrug chemotherapy for recurrent ovarian cancer Japanese women, a weekly carboplatin and paclitaxel chemotherapy in a meeting, can significantly prolong survival, and patients can be tolerated. (Int J Cancer YORK 2005,15:45)

The case control study included surgery and platinum-based adjuvant chemotherapy complete remission for at least 6 months after the recurrence of ovarian cancer patients. Of the 68 patients, 27 patients received a weekly meeting of Taxol and carboplatin chemotherapy (WTJ) (Group I), carboplatin (AUC area under the curve for 2) plus paclitaxel (80 mg/m2); The remaining 41 patients (Group II) to platinum-based (P ) other chemotherapy, 37 patients with CAP program, a monthly meeting of carboplatin and paclitaxel program four cases.

Tags: cancer, carboplatin, cases, chemotherapy, clinical, drug, drugs, eat, family, gene, group, growth, increased, intraperitoneal, method, ovarian, ovary, p53, paclitaxel, patients, preventive, prognosis, protein, rate, risk, screening, second, study, surgery, survival, syndrome, taxol, therapy, time, treatment, women

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women

Surgery

According to a medical examination and transvaginal ultrasound findings suspected ovarian cancer is often a laparotomy to be confirmed histology, and tumor stage and tumor debulking surgery. Histological need to be certified to remove ovarian cysts Mixed other causes, including non - epithelial ovarian cancer (such as interstitial or germ cell tumors), other primary site of tumor metastasis to the ovary (such as the adhesion of), or benign lesions, such as endometriosis. The adhesion is usually of signet ring cell tumor, representatives from primary adenocarcinoma of the stomach metastatic ovarian cancer. However, other parts of the original cancer, such as colon, appendix, the gallbladder and breast (special lobular invasive carcinoma) will also transfer to ovarian. At laparotomy surgery during the stage, right after the decision-making guidance provided important information, especially for patients with early (discussed below). Finally, the tumor debulking surgery (initial cytoreductive surgery) is the first of an important part of the operation because of residual tumor with a diameter of less than 1 cm larger than the residual tumor with a high survival rate.

Tags: abdominal, age, benign, bleeding, body, breast, cancer, carboplatin, carcinoma, care, cases, cause, cell, chemotherapy, cisplatin, clinical, cyst, cysts, diagnosis, drug, drugs, early, eat, ert, examination, exploration, gene, group, increased, intravenous, life, lymph, metastasis, metastatic, method, node, ovarian, ovary, paclitaxel, patients, pelvic, physical, poor, prognosis, quality, radiation, radiotherapy, rate, reduce, resection, residual, risk, screening, second, skin, staging, surface, surgery, surgical, survival, symptoms, syndrome, taxol, tea, therapy, time, treatment, tumor, tumors, usually, uterine

Abstract: The FDA approved a new treatment of advanced ovarian cancer on the first line of the short-term treatment programs, in the treatment of cisplatin infusion again, Bristol-Myers Squibb pharmaceutical factories paclitaxel (Taxol) 3 hours.

The United States Food and Drug Administration (FDA) approved a new treatment of advanced ovarian cancer on the first line of the short-term treatment programs, in the treatment of cisplatin injection again, Bristol-Myers Squibb pharmaceutical factories paclitaxel (Taxol) 3 hours.

Tags: administration, age, anti, blood, breast, cancer, cell, cells, cisplatin, clinical, drug, drugs, eat, fat, grams, head, infusion, injection, neck, ovarian, paclitaxel, patients, radiotherapy, reduce, risk, study, taxol, therapy, toxicity, treatment, women

Taxol is more 1990s, the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, chemotherapy, cisplatin, confidence, days, diet, dose, drug, drugs, eat, ert, gene, group, growth, incidence, infusion, injection, intravenous, life, metastasis, method, ovarian, paclitaxel, pain, patients, poor, psychological, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women

Although ovarian cancer chemotherapy drug developed considerable progress has been made, but patients with ovarian cancer and the overall survival rate has not improved markedly. Philadelphia's Fox Chase Hospital Dr. Bernard of ovarian cancer screening, treatment and prevention of, and possible future trends.

Tags: age, cancer, carboplatin, carcinoma, cause, cell, cells, chemotherapy, clinical, cox, drug, drugs, early, eat, exploration, grams, growth, incidence, method, ovarian, paclitaxel, patients, positive, preventive, protein, rate, reduce, response, risk, screening, surgical, survival, taxol, therapy, treatment, tumor